KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.90

Deciphering differential biomarkers for anti-interleukin-6 receptor and anti-tumour necrosis factor-α treatment response in rheumatoid arthritis by multiomics analysis.

Inoncent Agueusop, Daniel Margerie, Anne Remaury, Raphaël Brard, Francesca Frau, Emilie Gerard, Gilbert Thill, Yaligara Veeranagouda, Michel Didier, Markus Kohlmann, Matthias Herrmann, Nadine Biesemann

RMD Open 11(3) e005556

PMID40759562
PMCIDPMC12323545
DOI10.1136/rmdopen-2025-005556
发表日期2025-08-04
入排依据:The study is a Phase III randomized trial with drug interventions, but it is not in oncology and does not report a primary or key secondary time-to-event efficacy endpoint. The focus is on biomarker analysis for treatment response in rheumatoid arthritis.
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 7 张 PMC Figure,均未识别为 KM 图:Figure 1:森林图/亚组分析图;Figure 2:森林图/亚组分析图;Figure 3:森林图/亚组分析图;Figure 4:非 KM 图;Figure 5:非 KM 图;另有 2 张未列出。
摘要

摘要

OBJECTIVE: To identify blood-based predictive and pharmacodynamic biomarkers at different timepoints in patients with active rheumatoid arthritis (RA) treated with anti-interleukin-6 receptor (anti-IL-6R) and anti-tumour necrosis factor-α (anti-TNF-α). METHODS: This study used blood samples from the MONARCH trial (NCT02332590), a randomised, double-blind, phase III trial that compared the safety and efficacy of sarilumab (anti-IL-6R) and adalimumab (anti-TNF-α) monotherapy in patients with RA who were intolerant/inadequate responders to methotrexate. The study evaluated predictive biomarkers to anti-IL-6R and anti-TNF-α treatments at baseline and week 2 and pharmacodynamic biomarkers at week 2 and week 24 using Olink proteomics analysis (n=804 serum samples from 268 patients). Change in gene expression levels (n=522 peripheral blood samples from 261 patients) by both treatments was assessed using RNA sequencing analysis. RESULTS: Serum biomarkers most predictive to anti-IL-6R were different from those of anti-TNF-α; predictive biomarkers for anti-IL-6R were correlated with innate immune activation and synovial inflammation, while predictive biomarkers for anti-TNF-α seemed to be more T-cell and neutrophil-related. For baseline predictive biomarkers, we had to focus on relative prediction as the absolute prediction performance of single and combination biomarkers using cross-validation was limited. Additionally, the pharmacodynamic effects of anti-IL-6R and anti-TNF-α on biomarkers as well as pathway signatures were distinct. CONCLUSION: The unbiased analysis of serum proteins identified biomarkers most predictive of anti-IL-6R and anti-TNF-α at different timepoints that could explain the difference in the response rate in patients with RA. Further, both biomarker and pathway results highlighted a differentiated mode of action of both treatments.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(7,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Baseline most predictive biomarkers for anti-IL-6R and anti-TNF-α treatment response in patients with RA. ( A ) Top 30 baseline most predictive biomarkers* for anti-IL-6R treatment in patients with RA; ( B ) top 30 baseline most predictive biomarkers* for anti-TNF-α treatment in patients with RA; ( C ) overlap of top 30 baseline most predictive biomarkers for anti-IL-6R and anti-TNF-α treatments demonstrating only eight overlapping biomarkers between them. *Biomarkers in the random forest plots are arranged in descending order of relative importance in predicting treatment response from top to bottom; the horizontal red line separates the top 10 biomarkers; biomarkers only identified as predictive for either anti-TNF or anti-IL-6R are shown as empty circles. Anti-IL-6R, anti-interleukin-6 receptor; anti-TNF-α, anti-tumour necrosis factor-α; CDAI, Clinical Disease Activity Index; RA, rheumatoid arthritis. Please refer to online supplemental table 1 for the abbreviations used for biomarkers.
非 KM Figure
Figure 2Early most predictive biomarkers identified at week 2 after treatment initiation for anti-IL-6R and anti-TNF-α treatment response in patients with RA. ( A ) Top 30 early most predictive biomarkers* for anti-IL-6R treatment in patients with RA; ( B ) top 30 early most predictive biomarkers* for anti-TNF-α treatment in patients with RA; ( C ) overlap of top 30 early most predictive biomarkers between anti-IL-6R and anti-TNF-α treatment groups demonstrating six overlapping biomarkers between them; ( D ) heatmap ‡ for the top 30 early most predictive biomarkers † demonstrating deregulation of biomarkers at week 2 after anti-IL-6R and anti-TNF-α treatments. *Biomarkers in the random forest plots are arranged in descending order of relative importance in predicting treatment response from top to bottom; the horizontal red line separates the top 10 biomarkers; biomarkers only identified as predictive for either anti-TNF or anti-IL-6R are shown as empty circles. ‡ The Olink data in the heatmap are plotted as group means and show the raw values, therefore, each patient before and after treatment was not compared. † Biomarkers were selected from change in week 24 CDAI versus change in week 2 Olink analysis in at least one treatment arm. Anti-IL-6R, anti-interleukin-6 receptor; anti-TNF-α, anti-tumour necrosis factor-α; CDAI, Clinical Disease Activity Index; NPX, normalised protein expression; RA, rheumatoid arthritis. Please refer to online supplemental table 1 for the abbreviations used for biomarkers.
非 KM Figure
Figure 3Late predictive biomarkers identified at week 24 after treatment initiation for anti-IL-6R and anti-TNF-α treatment response in patients with RA. ( A ) Top 30 late biomarkers* predicting CDAI response at week 24 after anti-IL-6R treatment in patients with RA; ( B ) top 30 late biomarkers* predicting CDAI response at week 24 after anti-TNF-α treatment in patients with RA; ( C ) overlap of top 30 late predictive biomarkers between anti-IL-6R and anti-TNF-α treatment groups demonstrating six overlapping biomarkers between them; ( D ) heatmap ‡ for top 30 late predictive biomarkers † demonstrating deregulation of biomarkers observed at week 24 after anti-IL-6R and anti-TNF-α treatments. *Biomarkers in the random forest plots are arranged in descending order of relative importance in predicting treatment response from top to bottom; the horizontal red line separates the top 10 biomarkers; biomarkers only identified as predictive for either anti-TNF or anti-IL-6R are shown as empty circles. ‡ The Olink data in the heatmap are plotted as group means and show the raw values, therefore, each patient before and after treatment was not compared. † Biomarkers were selected from change in week 24 CDAI versus change in week 24 Olink analysis in at least one treatment arm. Anti-IL-6R, anti-interleukin-6 receptor; anti-TNF-α, anti-tumour necrosis factor-α; CDAI, Clinical Disease Activity Index; NPX, normalised protein expression; RA, rheumatoid arthritis. Please refer to online supplemental table 1 for the abbreviations used for biomarkers.
非 KM Figure
Figure 4Overlap of most predictive biomarkers identified at baseline, week 2 and week 24 predicting CDAI response at week 24 after anti-IL-6R and anti-TNF-α treatments. ( A ) Overlap of top 30 most predictive biomarkers for anti-IL-6R treatment response identified at baseline and week 2 demonstrating limited overlap; ( B ) overlap of top 30 most predictive biomarkers to anti-TNF-α treatment response identified at baseline and week 2 demonstrating limited overlap. Anti-IL-6R, anti-interleukin-6 receptor; anti-TNF-α, anti-tumour necrosis factor-α; CDAI, Clinical Disease Activity Index. Please refer to online supplemental table 1 for the abbreviations used for biomarkers.
非 KM Figure
Figure 5Pharmacodynamic biomarkers for anti-IL-6R and anti-TNF-α treatment. ( A ) Heatmaps ‡ for pharmacodynamic biomarkers* demonstrating deregulation of biomarkers at week 2 and week 24 after anti-IL-6R and anti-TNF-α treatments; ( B ) degree and variability of deregulation of pharmacodynamic biomarkers* at week 2 after anti-IL-6R and anti-TNF-α treatments; ( C ) degree and variability of deregulation of pharmacodynamic biomarkers* at week 24 after anti-IL-6R and anti-TNF-α treatments. ‡ The Olink data in the heatmap are plotted as group means and show the raw values, therefore, each patient before and after treatment was not compared. *The selection criteria for biomarkers were FDR <0.05 and FC ≥1.2 or FC ≤1/1.2 in at least one treatment arm at week 2 ( A and B ) or Week 24 ( A and C ). Anti-IL-6R, anti-interleukin-6 receptor; anti-TNF-α, anti-tumour necrosis factor-α; BL, baseline; FC, fold change; FDR, false discovery rate; LS mean, least-square mean. Please refer to online supplemental table 1 for the abbreviations used for biomarkers.
非 KM Figure
Figure 6RNA sequencing analysis at baseline and week 2 after anti-IL-6R and anti-TNF-α treatment initiation. ( A ) Venn diagrams of deregulated genes identified at week 2 in anti-IL-6R and anti-TNF-α treatment arms demonstrating limited overlap of genes between both treatment arms; ( B ) RA pathway with deregulation of genes by anti-IL-6R treatment; ( C ) RA pathway with deregulation of genes by anti-TNF-α treatment; ( D ) Canonical pathway analysis identifying signalling pathways that were significantly activated or inhibited by anti-IL-6R treatment; ( E ) Canonical pathway analysis identifying signalling pathways that were significantly activated or inhibited by anti-TNF-α treatment. Anti-IL-6R, anti-interleukin-6 receptor; anti-TNF-α, anti-tumour necrosis factor-α; IL, interleukin; MSP, macrophage-stimulating protein; RA, rheumatoid arthritis; RON, recepteur d'origine nantais; TREM1, triggering receptor expressed on myeloid cells 1.
非 KM Figure
Figure 7Graphical summary of biological themes regulated by ( A ) anti-IL-6R treatment and ( B ) anti-TNF-α treatments. Anti-IL-6R, anti-interleukin-6 receptor; anti-TNF-α, anti-tumour necrosis factor-α.
非 KM Figure